IP Library Granted Patent US 7,982,004
Granted Patent B2
US 7,982,004 · App. 12/646,863 · Granted Jul 19, 2011

Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,982,004
App. No.
12/646,863
Granted
Jul 19, 2011
Kind
B2
Abstract

A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.

Claims (10)

1. An isolated protein, comprising the polypeptide sequence of SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8.

2. A composition, comprising: a physiologically acceptable carrier; and a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

3. The composition of claim 2 , wherein the protein comprises the amino acid sequence of SEQ ID NO: 4.

4. The composition of claim 2 , further comprising an adjuvant.

5. The composition of claim 2 , wherein the protein further comprises a heterologous polypeptide.

6. The isolated protein of claim 1 , further comprising a heterologous polypeptide.

7. An isolated protein, comprising the polypeptide sequence of SEQ ID NO: 4.

8. The isolated protein of claim 7 , further comprising a heterologous polypeptide.

9. A composition, comprising the protein of claim 7 and a physiologically acceptable carrier.

10. The composition of claim 9 , further comprising an adjuvant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2010
From: CHALLITA-EID, PIA M.; RAITANO, ARTHUR B.; FARIS, MARY; HUBERT, RENE S.; MORRISON, KAREN JANE MEYRICK; MORRISON, ROBERT KENDALL; GE, WANGMAO; JAKOBOVITS, AYA
To: AGENSYS, INC.
Reel/Frame 023799/0614 →